Faculty Profile: James A. Hellinger, M.D., M.Sc.

Assistant Professor
Department of Medicine
Tufts University School of Medicine

Tufts Medical Center
Division of Geographic Medicine and Infectious Diseases
750 Washington Street
Boston, MA 02111

1. Hellinger J. HIV blip synching: get the timing right. Clin Infect Dis. 2005 Nov 1;41(9):1333-4. Epub 2005 Sep 29.
   
   
2. Hellinger J, Cohen C, Morris A, Sheble-Hall S, Gordon D, Foy C, Jackson-Pope L, Shevitz A, van Schaic E. Pilot study of saquinavir and lopinavir/ritonavir twice daily in protease inhibitor-naive HIV-positive patients. HIV Clin Trials. 2005 Mar-Apr;6(2):107-17.
   
   
3. Fleishman JA, Gebo KA, Reilly ED, Conviser R, Christopher Mathews W, Todd Korthuis P, Hellinger J, Rutstein R, Keiser P, Rubin H, Moore RD; HIV Research Network. Hospital and outpatient health services utilization among HIV-infected adults in care 2000-2002. Med Care. 2005 Sep;43(9 Suppl):III40-52.
   
   
4. Gebo KA, Fleishman JA, Conviser R, Reilly ED, Korthuis PT, Moore RD, Hellinger J, Keiser P, Rubin HR, Crane L, Hellinger FJ, Mathews WC; HIV Research Network. Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001. J Acquir Immune Defic Syndr. 2005 Jan 1;38(1):96-103.
   
   
5. Cohen C, Hellinger J, Johnson M, Staszewski S, Wintfeld N, Patel K, Green J. Patient acceptance of self-injected enfuvirtide at 8 and 24 weeks. HIV Clin Trials. 2003 Sep-Oct;4(5):347-57.
   
   
6. Hellinger JA, Cohen CJ, Stein AJ, Gallant JE, Gathe J, Keiser P. Efficacy of nelfinavir in patients switched from ritonavir/saquinavir combination antiretroviral therapy. HIV Clin Trials. 2000 Sep-Oct;1(2):25-8.
   
   
7. Hellinger JA, Iwane MK, Smith JJ, Fleishman AN, Torres RA, Schrader S, Perez G, Cohen CJ, Skowron G, Giordano MF, Accetta G, Cooper EC, Frost KR. A randomized study of the safety and antiretroviral activity of hydroxyurea combined with didanosine in persons infected with human immunodeficiency virus type 1. American Foundation for AIDS Research Community-Based Clinical Trials Network. J Infect Dis. 2000 Feb;181(2):540-7.
   
   
8. Cohen CJ, Hellinger JA, Day J, Salitsky N, Shevitz A, Zackin R, DeGruttola V. Lack of effect of cimetidine on lymphocyte subsets in patients infected with human immunodeficiency virus type 1. Clin Infect Dis. 1996 Nov;23(5):1049-54.
   
   
9. Marlink R, Kanki P, Thior I, Travers K, Eisen G, Siby T, Traore I, Hsieh CC, Dia MC, Gueye EH, Hellinger J, Gueye-Ndiaye A, Sankale JL, Ndoye I, Mboup S, Essex M. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science. 1994 Sep 9;265(5178):1587-90.
   
   
10. Hellinger J, Marlink R, Kaptue L, Zekeng L, Essex M. Are tuberculosis patients a ‘sentinel’ population for HIV epidemic in Africa? Trans R Soc Trop Med Hyg. 1990 Mar-Apr;84(2):292.